Mateon Therapeutics (QB) Stock Price

0.025 (7.25%)
Best deals to access real time data!
Small Cap Basic
Monthly Subscription
for only
Ultimate Trader (Monthly)
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Mateon Therapeutics Inc (QB) MATN OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.025 7.25% 0.37 16:51:35
Open Price Low Price High Price Close Price Prev Close
0.358 0.358 0.37 0.37 0.345
Bid Price Ask Price Spread News
0.36 0.40 0.04 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
143 725,896 $ 0.364249 $ 264,407 - 0.076 - 0.38
Last Trade Time Type Quantity Stock Price Currency
15:59:44 9,000 $ 0.37 USD

Mateon Therapeutics (QB) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 33.15M 89.58M 26.84M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
491.00 $ - 0.00% - -

more financials information »

Mateon Therapeutics (QB) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical MATN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.290.380.260.3286994541,9340.0827.59%
1 Month0.210.380.20110.2728457337,4720.1676.19%
3 Months0.1720.380.170.2459731203,9790.198115.12%
6 Months0.230.380.160.2358842166,4630.1460.87%
1 Year0.160.380.0760.2068445201,4070.21131.25%
3 Years0.1850.380.050.197619198,7780.185100.0%
5 Years0.340.8890.050.244388695,6410.038.82%

Mateon Therapeutics (QB) Description

Mateon has three major business segments: 1) PointR- developer of vision grid/cluster computing/AI to support drug development. 2) Mateon/Oxigene- developer of Vascular Disrupting Agent (CA4P and Oxi4503). FDA granted CA4P rare pediatric designation for pediatric melanoma in 2020 and OXi4503 rare pediatric designation for pediatric ALL. 3) Oncotelic- developer of OT-101 - an antisense against TGF-beta- for the treatment of cancers. OT-101 completed phase 2 with good safety and efficacy against pancreatic cancer, glioblastoma, and melanoma. OT-101 also been granted rare pediatric designation against pediatric DIPG in 2019. OT-101 is also being deployed against COVID-19. OT-101 is in phase 2 clinical trial against COVID. We are also developing Artemisinin in phase 4 clinical trial against COVID. It is approved by India for symptoms frequently observed in COVID. It is being launch by end of 2020. Global launch will be soon after.

Your Recent History
Mateon The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.